US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ODDITY Tech Ltd.

71.90

-2.0900-2.82%

Volume:222.27K

Turnover:16.00M

Market Cap:4.01B

PE:41.39

High:73.86

Open:72.50

Low:71.09

Close:73.99

Loading ...

Overview Company News Filings

Oddity Tech Q1 Adjusted Earnings, Revenue Rise; 2025 Outlook Raised -- Shares Climb

MT Newswires Live

Oddity Tech Ltd reports results for the quarter ended March 31 - Earnings Summary

Oddity Tech (ODD) Q1 Earnings and Revenues Beat Estimates

Earnings Flash (ODD) Oddity Tech Q1 Net Revenue $268.1 Million vs. FactSet Est $260.6 Million

MT Newswires Live

Earnings Flash (ODD) Oddity Tech Q1 Adjusted EPS $0.69 vs. FactSet Est $0.62

MT Newswires Live

ODDITY Tech Q1 Adj. EPS $0.69 Beats $0.62 Estimate, Sales $268.08M Beat $260.69M Estimate

Oddity Tech Reports Record First Quarter Results, Raises Full Year Outlook

THOMSON REUTERS

Oddity Tech Outlook FY Gross Margin 71%

THOMSON REUTERS

Oddity Tech Q1 EPS USD 0.63

THOMSON REUTERS

Press Release: ODDITY Tech Reports Record First Quarter Results, Raises Full Year Outlook

Calendar of U.S. Earnings Expected in the Week Ahead

Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

ODDITY Tech Is Maintained at Overweight by JP Morgan

NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism

3 Growth Companies To Watch With Up To 32% Insider Ownership

Simply Wall St.

ODDITY Tech Is Maintained at Overweight by Keybanc

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Cboe Global Markets Reports Trading Volume for March 2025

Oddity Tech (NasdaqGM:ODD) Surges 13% Last Quarter Following Strong Earnings with Sales Hitting US$124M

Simply Wall St.

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ODD/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ODD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","market":"US","secType":"STK","nameCN":"ODDITY Tech Ltd.","latestPrice":71.9,"timestamp":1749826643025,"preClose":73.99,"halted":0,"volume":222270,"delay":0,"floatShares":38704922,"shares":55828291,"eps":1.736982,"marketStatus":"Trading","change":-2.09,"latestTime":"06-13 10:57:28 EDT","open":72.5,"high":73.86,"low":71.089,"amount":16004426.878800001,"amplitude":0.037451,"askPrice":72.06,"askSize":406,"bidPrice":71.83,"bidSize":11,"shortable":3,"etf":0,"ttmEps":1.736982,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749844800000},"marketStatusCode":2,"adr":0,"listingDate":1689739200000,"exchange":"NASDAQ","adjPreClose":73.99,"preHourTrading":{"tag":"盘前","latestPrice":72,"preClose":73.99,"latestTime":"09:29 EDT","volume":2335,"amount":167094.86495,"timestamp":1749821395076},"postHourTrading":{"tag":"盘后","latestPrice":74.49,"preClose":73.99,"latestTime":"19:57 EDT","volume":42050,"amount":3111441.29,"timestamp":1749772668731},"volumeRatio":0.503565,"impliedVol":0.5684,"impliedVolPercentile":0.276},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ODD\",,,,,undefined,":{"symbol":"ODD","floatShares":38704922,"roa":"14.35%","roe":"32.25%","lyrEps":1.769608,"volumeRatio":0.503565,"shares":55828291,"dividePrice":0,"high":73.86,"amplitude":0.037451,"preClose":73.99,"low":71.089,"week52Low":32.71,"pbRate":"12.17","psRate":"5.71","week52High":79.1804,"institutionHeld":0,"latestPrice":71.9,"committee":-0.947242,"eps":1.736982,"divideRate":0,"volume":222270,"delay":0,"ttmEps":1.736982,"open":72.5,"prevYearClose":42.02,"prevWeekClose":77.35,"prevMonthClose":74.43,"prevQuarterClose":43.26,"fiveDayClose":77.35,"twentyDayClose":63.25,"sixtyDayClose":43.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ODD\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531709873","title":"Oddity Tech Q1 Adjusted Earnings, Revenue Rise; 2025 Outlook Raised -- Shares Climb","url":"https://stock-news.laohu8.com/highlight/detail?id=2531709873","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531709873?lang=en_us&edition=fundamental","pubTime":"2025-04-30 16:07","pubTimestamp":1746000423,"startTime":"0","endTime":"0","summary":"Oddity Tech  reported Q1 adjusted earnings late Tuesday of $0.69 per diluted share, up from $0.61 a year earlier.Analysts polled by FactSet expected $0.62.Revenue for the quarter ended March 31 was $268.1 million compared with $211.6 million a year earlier. Analysts surveyed by FactSet expected $260.6 million.For Q2, the company expects adjusted earnings of $0.85 to $0.89 per diluted share on revenue of $235 million to $239 million. Analysts expect adjusted earnings of $0.83 on revenue of $233.5 million.The company raised its 2025 adjusted EPS guidance to $1.99 to $2.04 from $1.94 to $1.98. Analysts expect $1.92. The company also raised annual revenue guidance to $790 million to $798 million from $776 million to $785 million. Analysts polled by FactSet expect $785.6 million.Shares were up 20% in premarket activity Wednesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODD"],"gpt_icon":0},{"id":"2531132337","title":"Oddity Tech Ltd reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2531132337","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531132337?lang=en_us&edition=fundamental","pubTime":"2025-04-30 05:42","pubTimestamp":1745962976,"startTime":"0","endTime":"0","summary":"Oddity Tech Ltd reports results for the quarter ended March 31 - Earnings SummaryOddity Tech Ltd ODD.OQ reported quarterly adjusted earnings of 69 cents per share for the quarter ended March 31, highe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL8N3R73JL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2531717035","title":"Oddity Tech (ODD) Q1 Earnings and Revenues Beat Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2531717035","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531717035?lang=en_us&edition=fundamental","pubTime":"2025-04-30 05:40","pubTimestamp":1745962805,"startTime":"0","endTime":"0","summary":"Oddity Tech  came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.61 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.52%. A quarter ago, it was expected that this online retailer of cosmetics and beauty products would post earnings of $0.13 per share when it actually produced earnings of $0.20, delivering a surprise of 53.85%.Oddity Tech , which belongs to the Zacks Internet - Software industry, posted revenues of $268.08 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.86%. This compares to year-ago revenues of $211.63 million. The company has topped consensus revenue estimates four times over the last four quarters.Oddity Tech shares have added about 7.2% since the beginning of the year versus the S&P 500's decline of -6%.While Oddity Tech has outperformed the market so far th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oddity-tech-odd-q1-earnings-214005878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ODD"],"gpt_icon":0},{"id":"2531908747","title":"Earnings Flash (ODD) Oddity Tech Q1 Net Revenue $268.1 Million vs. FactSet Est $260.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2531908747","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531908747?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:52","pubTimestamp":1745959959,"startTime":"0","endTime":"0","summary":"Earnings Flash (ODD) Oddity Tech Q1 Net Revenue $268.1 Million vs. FactSet Est $260.6 Million","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODD"],"gpt_icon":0},{"id":"2531579702","title":"Earnings Flash (ODD) Oddity Tech Q1 Adjusted EPS $0.69 vs. FactSet Est $0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2531579702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531579702?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:51","pubTimestamp":1745959873,"startTime":"0","endTime":"0","summary":"Earnings Flash (ODD) Oddity Tech Q1 Adjusted EPS $0.69 vs. FactSet Est $0.62","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ODD"],"gpt_icon":0},{"id":"2531791948","title":"ODDITY Tech Q1 Adj. EPS $0.69 Beats $0.62 Estimate, Sales $268.08M Beat $260.69M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2531791948","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531791948?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:10","pubTimestamp":1745957403,"startTime":"0","endTime":"0","summary":"ODDITY Tech (NASDAQ:ODD) reported quarterly earnings of $0.69 per share which beat the analyst consensus estimate of $0.62 by 11.29 percent. This is a 13.11 percent increase over earnings of $0.61 per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/45083095/oddity-tech-q1-adj-eps-0-69-beats-0-62-estimate-sales-268-08m-beat-260-69m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2531579974","title":"Oddity Tech Reports Record First Quarter Results, Raises Full Year Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531579974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531579974?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957134,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA5WVSZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","BK4183"],"gpt_icon":0},{"id":"2531799262","title":"Oddity Tech Outlook FY Gross Margin 71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531799262","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531799262?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957134,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nPLX689530:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4183","ODD"],"gpt_icon":0},{"id":"2531254799","title":"Oddity Tech Q1 EPS USD 0.63","url":"https://stock-news.laohu8.com/highlight/detail?id=2531254799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531254799?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957134,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nPLX689530:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ODD","BK4183"],"gpt_icon":0},{"id":"2531544791","title":"Press Release: ODDITY Tech Reports Record First Quarter Results, Raises Full Year Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2531544791","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531544791?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957100,"startTime":"0","endTime":"0","summary":"-- First quarter net revenue of $268 million, up 27% year-over-year. NEW YORK, April 29, 2025  -- ODDITY Tech Ltd.  today announced its financial results for the first quarter ended March 31, 2025.\"Our Q125 results exceeded our expectations across all metrics and allow us to raise our full year outlook. We delivered an outstanding result for our biggest quarter of the year, setting us up to overdeliver on our financial algorithm in 2025,\" said Oran Holtzman, ODDITY co-founder and CEO. \"The beauty industry continues to transform, as we said it would, with consumers moving online and towards high performance products, in our view. The structural changes in the industry, including the growth of online, are only strengthening as the store model is less suited for the current environment. It only makes our opportunity bigger.\". ODDITY achieved a number of objectives during the first quarter, which include:. Results for the first quarter ended March 31, 2025 are presented below in comparison","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD","BK4183"],"gpt_icon":0},{"id":"2531204243","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2531204243","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531204243?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:00","pubTimestamp":1745920800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·A. O. Smith Corp                                  1Q       .91   6:55 AM. ·Altria Grp Inc.                                    1Q      1.19   7:00 AM. ·Anywhere Rl Est                                  1Q      (.59)  7:30 AM. ·Arch Capital Gp                                  1Q      1.32   4:00 PM. ·Artisan Ptrns Asst                               1Q       .75   4:30 PM. ·Asbury Auto Gp                                    1Q      6.68   7:00 AM. ·Banco de Chile                                    1Q       .61   5:45 AM. ·BP PLC Spo ADR                                     1Q       .55   2:00 AM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PPG","AEYE","KRG","CZR","KHC","PUMP","BRSP","HTLD","HI","HON","PFE","CWK","AMSF","NSP","MIR","ODD","ENSG","KAI","KO","BBIO","LH","FFIC","CBU","ESS","RCL","INCY","AMX","FELE","NMIH","AOS","HRZN","LOGI","OKE","OI","NEO","BXP","LGIH","OMF","DB","ROG","BXC","ENVA","FCF","AMT","APAM","HIW","PCAR","CECO","HOUS","CWH"],"gpt_icon":1},{"id":"2529680520","title":"Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529680520","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529680520?lang=en_us&edition=fundamental","pubTime":"2025-04-23 22:04","pubTimestamp":1745417040,"startTime":"0","endTime":"0","summary":"— Oral presentation Tuesday, June 3, 2025 in Chicago —。“Safety and efficacy data from NEXICART-2, the first US trial of CAR-T in R/R light chain  amyloidosis, NXC-201”。Session Name: 652. Oral Abstract Session – Hematologic Malignancies—Plasma Cell Dyscrasia. About AL AmyloidosisAL amyloidosis is caused by abnormal plasma cells in the bone marrow, which produce misfolded amyloid proteins that build-up in the heart, kidney, liver, and other organs. This build-up causes progressive and widespread organ damage, including heart and renal failure, leading to high mortality rates.The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immix-biopharma-nxc-201-nexicart-140400135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAR","IE0034390439.USD","AL","BK4139","BK4022","BK4572","BK4230","BK4183","IMMX","IE00B19Z6F94.USD","NXC","BK4104","ODD"],"gpt_icon":0},{"id":"2529308538","title":"ODDITY Tech Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2529308538","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529308538?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:59","pubTimestamp":1745333940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2025 10:59 ET (14:59 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2529307753","title":"NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism","url":"https://stock-news.laohu8.com/highlight/detail?id=2529307753","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529307753?lang=en_us&edition=fundamental","pubTime":"2025-04-22 04:05","pubTimestamp":1745265900,"startTime":"0","endTime":"0","summary":"The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder. Plan to initiate first-in-human U.S. clinical trials of lead drug candidate for treating ASD in 2026. BOSTON, April 21, 2025  -- NeuroNOS, a biopharmaceutical company focused on developing treatments for autism and Alzheimer disorders, and a subsidiary of Beyond Air , today announced that the U.S. Food and Drug Administration  has granted Orphan Drug Designation  to its lead investigational therapy, BA-102, for the treatment of Phelan-McDermid Syndrome , a syndrome associated with Autism Spectrum Disorder . The company is on track to initiate first-in-human clinical trials for ASD in the United States in 2026.PMS is a rare genetic disorder most commonly caused by deletions or mutations affecting the SHANK3 gene leading to a range of symptoms, including global developmental delay, intellectual disability, severe speech impairments, and in many cases features ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuronos-granted-fda-orphan-drug-200500846.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","BK4183","XAIR","ODD"],"gpt_icon":0},{"id":"2529808212","title":"3 Growth Companies To Watch With Up To 32% Insider Ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2529808212","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529808212?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:35","pubTimestamp":1745235329,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped by 1.1%, though it has risen by 5.9% over the past year, with earnings forecasted to grow by 13% annually. In this context, growth companies with significant insider ownership can be appealing as they often indicate strong confidence from those closest to the company's operations and strategies.Top 10 Growth Companies With High Insider Ownership In The United States. Click here to see the full list of 201 stocks from our Fast Growing US Companies With High Insider Ownership screener.Overview: Oddity Tech Ltd. is a consumer tech company focused on creating digital-first brands in the beauty and wellness sectors, with a market cap of approximately $2.34 billion.Overview: Cloudflare, Inc. is a cloud services provider offering various solutions to businesses globally, with a market cap of approximately $37.21 billion.Cloudflare is experiencing substantial growth, with revenue expected to increase by 18.7% annually, outpacing the US","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-growth-companies-watch-32-113529082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0327786744.USD","LU2286300806.USD","BK4116","BK4588","BK4539","LU2242644610.SGD","LU0456842615.SGD","LU0455707207.USD","BK4232","BK4503","LU0572944931.SGD","BK4607","BK4526","YMM","NET","BK4585","BK4196","LU0502904849.HKD","BK4022","ODD","BK4613","BK4548","BK4554","BK4560"],"gpt_icon":1},{"id":"2527212810","title":"ODDITY Tech Is Maintained at Overweight by Keybanc","url":"https://stock-news.laohu8.com/highlight/detail?id=2527212810","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527212810?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:55","pubTimestamp":1744808100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ODD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 08:55 ET (12:55 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ODD"],"gpt_icon":0},{"id":"2525881534","title":"Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2525881534","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525881534?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:00","pubTimestamp":1744117200,"startTime":"0","endTime":"0","summary":"Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan. SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. , a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates , today announced that the Japan Ministry of Health, Labour and Welfare  has granted Orphan Drug designation  to delpacibart etedesiran  for the treatment of myotonic dystrophy type 1 , an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. Del-desiran is the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. Del-desiran has also received Breakthrough Therapy, Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration  and Orphan designation by the European Medicines Agency .About the Phase 3 HARBOR TrialThe global Phase 3 HA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/avidity-biosciences-receives-orphan-drug-130000338.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/avidity-biosciences-receives-orphan-drug-130000338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4183","BK4585","BK4505","RNA","ODD","BK4139"],"gpt_icon":0},{"id":"2524219878","title":"Cboe Global Markets Reports Trading Volume for March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524219878","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524219878?lang=en_us&edition=fundamental","pubTime":"2025-04-04 04:30","pubTimestamp":1743712200,"startTime":"0","endTime":"0","summary":"CHICAGO, April 3, 2025 /PRNewswire/ -- Cboe Global Markets, Inc. , the world's leading derivatives and securities exchange network, today reported March trading volume statistics across its global business lines and provided guidance for selected revenue per contract/net revenue capture metrics for the first quarter of 2025.The data sheet \"Cboe Global Markets Monthly Volume & RPC/Net Revenue Capture Report\" contains an overview of certain March trading statistics and market share by business segment, volume in select index products, and RPC/net capture, which is reported on a one-month lag, across business lines.March and First Quarter 2025 Trading Volume Highlights. Total volume across Cboe's four options exchanges in the first quarter achieved an all-time high of 1.1 billion contracts, with an ADV of 18.2 million contracts traded, and included a multiply-listed options ADV record of 13.4 million contracts.Cboe's proprietary product suite set several new trading volume records for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/cboe-global-markets-reports-trading-203000462.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cboe-global-markets-reports-trading-203000462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4532","BK4183","ODD","ADV","BK4585","BK4009","BK4112","BK4588","CBOE"],"gpt_icon":0},{"id":"2524921208","title":"Oddity Tech (NasdaqGM:ODD) Surges 13% Last Quarter Following Strong Earnings with Sales Hitting US$124M","url":"https://stock-news.laohu8.com/highlight/detail?id=2524921208","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524921208?lang=en_us&edition=fundamental","pubTime":"2025-04-04 01:54","pubTimestamp":1743702899,"startTime":"0","endTime":"0","summary":"Oddity Tech (NasdaqGM:ODD) recently reported a last-quarter price move of 13%, which coincides with a series of impactful company events. Notably, the company released strong fourth-quarter results, with sales increasing to $124 million from $97 million year-over-year, alongside an active share buyback program that saw 2.35 million shares repurchased, reflecting positive investor support. Additionally, Oddity Tech issued optimistic guidance for 2025, with expectations for increased revenue...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/5221000-choice1-main-header/1585186890345"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/household/nasdaq-odd/oddity-tech/news/oddity-tech-nasdaqgmodd-surges-13-last-quarter-following-str","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ODD"],"gpt_icon":0},{"id":"2524025521","title":"Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2524025521","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524025521?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., April 03, 2025----Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of tecarfarin, a new Phase 3-ready oral vitamin K antagonist anticoagulant, today announced its participation in a series of high-profile conferences throughout the second quarter of 2025, underscoring the Company’s commitment to advancing innovation and clinical development in anticoagulation therapy.Chief Operating Officer, Jeff Cole and Chief Medical Officer, Dr. James Ferguson will represent the Company at the 18th National Conference on Anticoagulation Therapy in Washington, D.C. from April 3-5, engaging with leading experts and key opinion leaders in anticoagulation therapy.Cadrenal is opportunistically pursuing business development initiatives with a longer-term focus to build a pipeline of specialized cardiovascular therapeutics. For more information, visit www.cadrenal.com and connect with us on LinkedIn.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cadrenal-therapeutics-participates-key-medical-120000485.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4183","BK4139","BK4007","CVKD","ODD"],"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":3,"totalSize":162,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ODD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-29","symbol":"ODD","fiscalQuarterEnding":"2025/03","expectedEps":0.53,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1745899200000,"reportTimeType":"post","actualEps":0.63},{"market":"US","date":"2025-02-25","symbol":"ODD","fiscalQuarterEnding":"2024/12","expectedEps":0.08,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740459600000,"reportTimeType":"post","actualEps":0.06},{"market":"US","date":"2024-11-06","symbol":"ODD","fiscalQuarterEnding":"2024/09","expectedEps":0.16,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":0.29},{"market":"US","date":"2024-08-07","symbol":"ODD","fiscalQuarterEnding":"2024/06","expectedEps":0.58,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"post","actualEps":0.71},{"market":"US","date":"2024-05-07","symbol":"ODD","fiscalQuarterEnding":"2024/03","expectedEps":0.41,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715054400000,"reportTimeType":"post","actualEps":0.53}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ODD\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ODD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1111,"buy":0.5556,"hold":0.3333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5556,"analysts":9,"updateTime":1738382400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ODD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ODD","date":"2025-06-11","current":37.374962,"percent":0.71828,"low":20.831575,"twenty":24.87686,"median":31.168388,"eighty":42.357153,"high":144.174884,"avg":34.913406,"sd":17.352714,"marketCap":3974416036},"quantilePoints":[{"date":"2023-07-21","current":130.121737,"twenty":124.979326,"median":126.90773,"eighty":128.836134,"marketCap":2827285100},{"date":"2023-07-28","current":127.857619,"twenty":126.192061,"median":128.560276,"eighty":129.606455,"marketCap":2778090339},{"date":"2023-08-04","current":144.174884,"twenty":128.138682,"median":130.121737,"eighty":138.668132,"marketCap":3132631890},{"date":"2023-08-11","current":59.921033,"twenty":128.138682,"median":131.59899,"eighty":138.150305,"marketCap":3096718967},{"date":"2023-08-18","current":49.805463,"twenty":52.028567,"median":129.262933,"eighty":135.506534,"marketCap":2573946329},{"date":"2023-08-25","current":45.155781,"twenty":48.598524,"median":91.807378,"eighty":132.13135,"marketCap":2333650744},{"date":"2023-09-01","current":45.716381,"twenty":47.266275,"median":50.709145,"eighty":131.711973,"marketCap":2362622552},{"date":"2023-09-08","current":40.286255,"twenty":46.134083,"median":49.805463,"eighty":131.410685,"marketCap":2081993665},{"date":"2023-09-15","current":40.648996,"twenty":43.649855,"median":48.206104,"eighty":130.121737,"marketCap":2100740129},{"date":"2023-09-22","current":30.701094,"twenty":40.692965,"median":47.574055,"eighty":129.262933,"marketCap":1586632553},{"date":"2023-09-29","current":31.151773,"twenty":36.878686,"median":46.562777,"eighty":127.857619,"marketCap":1609923614},{"date":"2023-10-06","current":28.491671,"twenty":32.503808,"median":45.749357,"eighty":123.693723,"marketCap":1472449544},{"date":"2023-10-13","current":31.976185,"twenty":32.503808,"median":44.402818,"eighty":59.921033,"marketCap":1652529215},{"date":"2023-10-20","current":29.832714,"twenty":31.459553,"median":41.803173,"eighty":57.306257,"marketCap":1541754654},{"date":"2023-10-27","current":29.832714,"twenty":31.15617,"median":40.714949,"eighty":54.667412,"marketCap":1541754654},{"date":"2023-11-03","current":29.678824,"twenty":30.355941,"median":40.467625,"eighty":50.479578,"marketCap":1533801609},{"date":"2023-11-10","current":30.298177,"twenty":30.305454,"median":36.878686,"eighty":50.003322,"marketCap":1598562121},{"date":"2023-11-17","current":37.221321,"twenty":30.355941,"median":36.411519,"eighty":49.783479,"marketCap":1963834134},{"date":"2023-11-24","current":37.016749,"twenty":30.445709,"median":37.119035,"eighty":49.462508,"marketCap":1953040715},{"date":"2023-12-01","current":36.693741,"twenty":30.5941,"median":37.016749,"eighty":48.26876,"marketCap":1935998475},{"date":"2023-12-08","current":40.591374,"twenty":30.734071,"median":37.17287,"eighty":48.041138,"marketCap":2141641505},{"date":"2023-12-15","current":46.060981,"twenty":30.923136,"median":37.910406,"eighty":47.753992,"marketCap":2430223438},{"date":"2023-12-22","current":50.712301,"twenty":31.153971,"median":38.59949,"eighty":48.041138,"marketCap":2675631695},{"date":"2023-12-29","current":50.884572,"twenty":31.160567,"median":38.868664,"eighty":49.761494,"marketCap":2684720890},{"date":"2024-01-05","current":46.7716,"twenty":31.28148,"median":39.765881,"eighty":49.183424,"marketCap":2467716366},{"date":"2024-01-12","current":46.965405,"twenty":31.46395,"median":40.526773,"eighty":48.323896,"marketCap":2477941710},{"date":"2024-01-19","current":45.899477,"twenty":31.472743,"median":40.645209,"eighty":48.306372,"marketCap":2421702318},{"date":"2024-01-26","current":45.684138,"twenty":31.580467,"median":40.703957,"eighty":48.306372,"marketCap":2410340824},{"date":"2024-02-02","current":45.156558,"twenty":31.989432,"median":42.12028,"eighty":48.252127,"marketCap":2382505165},{"date":"2024-02-09","current":48.246671,"twenty":32.113484,"median":43.346019,"eighty":48.217673,"marketCap":2545542596},{"date":"2024-02-16","current":46.125583,"twenty":32.418946,"median":44.467474,"eighty":48.217673,"marketCap":2433631886},{"date":"2024-02-23","current":42.389454,"twenty":32.503808,"median":43.451996,"eighty":48.101679,"marketCap":2236509975},{"date":"2024-03-01","current":45.414965,"twenty":32.586249,"median":43.346019,"eighty":47.880595,"marketCap":2396138958},{"date":"2024-03-08","current":42.187798,"twenty":32.646706,"median":43.451996,"eighty":47.880595,"marketCap":2469420590},{"date":"2024-03-15","current":43.718187,"twenty":32.976471,"median":43.684021,"eighty":47.798976,"marketCap":2559000375},{"date":"2024-03-22","current":43.038127,"twenty":33.910804,"median":43.451996,"eighty":47.751391,"marketCap":2519193702},{"date":"2024-03-28","current":41.755726,"twenty":34.121582,"median":43.229275,"eighty":47.682483,"marketCap":2444129691},{"date":"2024-04-05","current":35.33401,"twenty":34.429566,"median":43.074483,"eighty":47.592295,"marketCap":2068240969},{"date":"2024-04-12","current":35.168853,"twenty":35.003425,"median":42.938568,"eighty":47.491972,"marketCap":2058573635},{"date":"2024-04-19","current":32.672059,"twenty":33.859301,"median":42.736957,"eighty":47.44561,"marketCap":1912426280},{"date":"2024-04-26","current":30.816464,"twenty":32.666988,"median":42.389454,"eighty":47.239294,"marketCap":1803810931},{"date":"2024-05-03","current":32.701204,"twenty":32.521826,"median":42.280345,"eighty":47.139393,"marketCap":1914132280},{"date":"2024-05-10","current":30.051334,"twenty":32.188614,"median":42.12028,"eighty":47.109682,"marketCap":2161502316},{"date":"2024-05-17","current":34.470881,"twenty":32.029175,"median":41.880975,"eighty":47.036466,"marketCap":2479387030},{"date":"2024-05-24","current":28.991908,"twenty":31.962852,"median":41.668069,"eighty":46.979437,"marketCap":2085300972},{"date":"2024-05-31","current":28.39104,"twenty":31.618936,"median":40.692965,"eighty":46.967038,"marketCap":2042082299},{"date":"2024-06-07","current":35.032218,"twenty":31.466148,"median":40.618291,"eighty":46.952485,"marketCap":2519762369},{"date":"2024-06-14","current":31.434913,"twenty":31.466148,"median":40.526773,"eighty":46.846969,"marketCap":2261018998},{"date":"2024-06-21","current":31.17401,"twenty":31.40776,"median":40.286255,"eighty":46.77806,"marketCap":2242252995},{"date":"2024-06-28","current":31.039605,"twenty":31.15617,"median":39.116208,"eighty":46.676851,"marketCap":2232585660},{"date":"2024-07-05","current":32.549682,"twenty":31.153971,"median":38.825596,"eighty":46.51104,"marketCap":2341201009},{"date":"2024-07-12","current":33.300768,"twenty":31.165014,"median":38.233414,"eighty":46.411983,"marketCap":2395224351},{"date":"2024-07-19","current":31.719535,"twenty":31.193823,"median":37.851188,"eighty":46.379683,"marketCap":2281491001},{"date":"2024-07-26","current":32.889648,"twenty":31.177172,"median":37.124419,"eighty":46.315081,"marketCap":2365653680},{"date":"2024-08-02","current":30.43083,"twenty":31.177172,"median":37.016749,"eighty":46.269497,"marketCap":2188798320},{"date":"2024-08-09","current":24.621128,"twenty":31.077829,"median":36.878686,"eighty":46.15167,"marketCap":2152403648},{"date":"2024-08-16","current":25.909103,"twenty":30.914687,"median":36.319047,"eighty":46.132383,"marketCap":2264999665},{"date":"2024-08-23","current":24.744722,"twenty":30.826367,"median":35.664326,"eighty":46.112663,"marketCap":2163208317},{"date":"2024-08-30","current":23.938111,"twenty":30.576415,"median":35.479654,"eighty":46.043754,"marketCap":2092693640},{"date":"2024-09-06","current":21.999645,"twenty":30.415298,"median":35.251431,"eighty":45.974846,"marketCap":1923230948},{"date":"2024-09-13","current":22.858294,"twenty":30.138302,"median":35.032218,"eighty":45.974846,"marketCap":1998294959},{"date":"2024-09-20","current":23.144511,"twenty":29.832714,"median":34.577614,"eighty":45.899477,"marketCap":2023316296},{"date":"2024-09-27","current":25.837549,"twenty":29.733784,"median":34.493388,"eighty":45.749357,"marketCap":2258744331},{"date":"2024-10-04","current":26.907033,"twenty":29.206161,"median":34.203986,"eighty":45.716381,"marketCap":2352239691},{"date":"2024-10-11","current":26.632604,"twenty":28.857503,"median":34.05976,"eighty":45.700078,"marketCap":2328248903},{"date":"2024-10-18","current":26.737148,"twenty":28.675661,"median":33.782046,"eighty":45.684138,"marketCap":2337388251},{"date":"2024-10-25","current":24.829219,"twenty":28.39104,"median":33.498422,"eighty":45.587236,"marketCap":2170595150},{"date":"2024-11-01","current":24.874957,"twenty":27.774359,"median":33.138619,"eighty":45.414965,"marketCap":2174593614},{"date":"2024-11-08","current":25.903059,"twenty":26.907033,"median":32.701204,"eighty":45.328829,"marketCap":2624135294},{"date":"2024-11-15","current":22.412856,"twenty":26.554196,"median":32.64481,"eighty":45.156558,"marketCap":2270556768},{"date":"2024-11-22","current":25.688798,"twenty":26.266873,"median":32.549682,"eighty":45.155781,"marketCap":2602429343},{"date":"2024-11-29","current":26.196259,"twenty":26.231703,"median":32.526331,"eighty":45.078881,"marketCap":2653838175},{"date":"2024-12-06","current":27.019473,"twenty":26.102043,"median":32.510933,"eighty":44.930453,"marketCap":2737234726},{"date":"2024-12-13","current":27.882156,"twenty":26.129486,"median":32.397731,"eighty":44.829243,"marketCap":2824629741},{"date":"2024-12-20","current":24.673876,"twenty":26.102043,"median":32.284642,"eighty":44.80743,"marketCap":2499611678},{"date":"2024-12-27","current":24.555468,"twenty":26.074468,"median":32.122117,"eighty":44.68052,"marketCap":2487616283},{"date":"2025-01-03","current":24.036731,"twenty":26.028044,"median":31.982415,"eighty":44.572573,"marketCap":2435065032},{"date":"2025-01-10","current":24.916329,"twenty":25.91918,"median":31.969518,"eighty":44.533395,"marketCap":2524173675},{"date":"2025-01-17","current":25.299744,"twenty":25.850651,"median":31.948814,"eighty":44.510542,"marketCap":2563015904},{"date":"2025-01-24","current":24.983991,"twenty":25.688798,"median":31.719535,"eighty":44.467474,"marketCap":2531028186},{"date":"2025-01-31","current":26.906704,"twenty":25.660605,"median":31.631647,"eighty":44.252135,"marketCap":2725810541},{"date":"2025-02-07","current":24.025454,"twenty":25.660605,"median":31.600943,"eighty":44.067933,"marketCap":2433922614},{"date":"2025-02-14","current":24.245353,"twenty":25.528357,"median":31.476041,"eighty":43.718187,"marketCap":2456199775},{"date":"2025-02-21","current":24.809199,"twenty":25.393274,"median":31.447233,"eighty":43.663521,"marketCap":2513320700},{"date":"2025-02-28","current":26.194867,"twenty":25.287339,"median":31.363758,"eighty":43.611255,"marketCap":2658543217},{"date":"2025-03-07","current":24.561126,"twenty":25.149762,"median":31.267028,"eighty":43.481918,"marketCap":2492733193},{"date":"2025-03-14","current":25.259729,"twenty":25.127573,"median":31.17401,"eighty":43.282433,"marketCap":2563635122},{"date":"2025-03-21","current":23.829518,"twenty":25.089994,"median":31.105558,"eighty":43.231428,"marketCap":2418481566},{"date":"2025-03-28","current":23.620487,"twenty":25.062794,"median":30.968449,"eighty":43.177394,"marketCap":2397266815},{"date":"2025-04-04","current":20.886583,"twenty":24.97973,"median":30.909153,"eighty":43.121556,"marketCap":2119800209},{"date":"2025-04-11","current":22.872376,"twenty":24.935811,"median":30.865977,"eighty":43.052669,"marketCap":2321340339},{"date":"2025-04-17","current":23.075906,"twenty":24.876099,"median":30.80242,"eighty":42.991494,"marketCap":2341996807},{"date":"2025-04-25","current":24.341093,"twenty":24.812177,"median":30.590011,"eighty":42.947303,"marketCap":2470401876},{"date":"2025-05-02","current":33.211688,"twenty":24.800183,"median":30.612672,"eighty":42.912727,"marketCap":3531697688},{"date":"2025-05-09","current":37.275211,"twenty":24.812177,"median":30.809442,"eighty":42.852836,"marketCap":3963808661},{"date":"2025-05-16","current":33.075187,"twenty":24.823197,"median":30.881482,"eighty":42.719469,"marketCap":3517182333},{"date":"2025-05-23","current":36.009954,"twenty":24.840888,"median":30.917059,"eighty":42.57047,"marketCap":3829262479},{"date":"2025-05-30","current":37.968215,"twenty":24.859184,"median":31.004027,"eighty":42.466444,"marketCap":4037502005},{"date":"2025-06-06","current":40.472479,"twenty":24.875718,"median":31.151773,"eighty":42.376534,"marketCap":4303802953},{"date":"2025-06-11","current":37.374962,"twenty":24.87686,"median":31.168388,"eighty":42.357153,"marketCap":3974416036}],"updateTime":1749792601395}}}